8-K: Merck Reports Strong First Quarter 2024 Results Driven by Oncology and Vaccine Sales

Merck's first quarter 2024 results show a 9% increase in total worldwide sales, reaching $15.8 billion, driven by strong growth in oncology and vaccine products.

Summary

• Merck's total worldwide sales for the first quarter of 2024 were $15.8 billion, a 9% increase compared to the same period in 2023, or 12% excluding foreign exchange impacts.
• Key growth drivers included oncology, with KEYTRUDA sales increasing by 20% to $6.9 billion (24% excluding foreign exchange), and vaccines, with GARDASIL/GARDASIL 9 sales growing by 14% to $2.2 billion (17% excluding foreign exchange).
• GAAP earnings per share (EPS) was $1.87, while non-GAAP EPS was $2.07, both including a $0.26 per share charge for the acquisition of Harpoon Therapeutics.
• The company has raised and narrowed its full-year 2024 sales outlook to between $63.1 billion and $64.3 billion and non-GAAP EPS to between $8.53 and $8.65.
• Merck received FDA approval for WINREVAIR, a new treatment for pulmonary arterial hypertension, and made progress in clinical development across various therapeutic areas.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong sales growth, increased financial outlook, and strategic acquisitions. The company's performance in key therapeutic areas and the approval of a new drug contribute to the positive outlook. However, some negative aspects such as declining sales in certain products and foreign exchange impacts temper the overall sentiment.

Positives

• Strong sales growth in oncology and vaccines drove overall revenue increase.
• KEYTRUDA and GARDASIL/GARDASIL 9 showed significant sales growth, indicating strong market demand.
• The company received FDA approval for WINREVAIR, a new treatment for pulmonary arterial hypertension.
• Merck is expanding its pipeline and portfolio through strategic acquisitions and business development.
• The full-year 2024 financial outlook has been raised and narrowed, indicating increased confidence in future performance.
• Non-GAAP gross margin increased to 81.2% from 76.9% in the prior year.

Negatives

• JANUVIA/JANUMET sales declined by 24% due to lower pricing and demand.
• LAGEVRIO sales decreased by 11% due to lower demand in certain Asia Pacific markets.
• ROTATEQ sales declined by 27% due to timing of shipments and public-sector buying patterns.
• The company experienced a negative impact from foreign exchange, particularly the devaluation of the Argentine peso.
• The first quarter GAAP and non-GAAP EPS included a charge of $0.26 per share for the acquisition of Harpoon.

Risks

• The company faces risks related to currency exchange rate fluctuations, particularly the devaluation of the Argentine peso.
• There are challenges inherent in new product development, including obtaining regulatory approval.
• The company is exposed to litigation, including patent litigation, and regulatory actions.
• Merck is dependent on the effectiveness of its patents and other protections for innovative products.
• The company faces competition from other pharmaceutical companies and technological advances.

Future Outlook

Merck has raised and narrowed its full-year 2024 financial outlook, expecting sales between $63.1 billion and $64.3 billion and non-GAAP EPS between $8.53 and $8.65. The company anticipates continued strong global demand for key growth products in oncology and vaccines.

Management Comments

• Merck has begun 2024 with continuing momentum in our business.
• We are harnessing the power of innovation to advance our deep pipeline and are maximizing the impact of our broad commercial portfolio for the benefit of patients.
• We drove strong growth across key therapeutic areas, executed strategic business development, and in the U.S., we are now launching WINREVAIR, a significant new product in the cardiometabolic space for adults with pulmonary arterial hypertension, a progressive and debilitating disease.
• We have important opportunities ahead of us across all areas of our business, and we are highly focused on realizing them.

Industry Context

Merck's strong performance in oncology and vaccines aligns with broader industry trends, where these therapeutic areas are experiencing significant growth. The approval of WINREVAIR also highlights the increasing focus on innovative treatments for rare diseases. The company's strategic acquisitions and pipeline development efforts position it well to compete in the biopharmaceutical market.

Comparison to Industry Standards

• Merck's 20% growth in KEYTRUDA sales is a strong performance compared to other oncology drugs in the same class, such as Bristol Myers Squibb's Opdivo, which has shown more modest growth in recent quarters.
• The 14% growth in GARDASIL/GARDASIL 9 sales is also impressive, outpacing the growth of other vaccine products from competitors like Pfizer and GSK.
• The approval of WINREVAIR positions Merck as a leader in the pulmonary arterial hypertension space, where there are limited treatment options.
• Merck's non-GAAP EPS of $2.07 is competitive with other large pharmaceutical companies, such as Johnson & Johnson and AbbVie, which have reported similar earnings per share in their recent quarterly results.
• The company's full-year sales outlook of $63.1 to $64.3 billion is in line with the expectations for a company of its size and portfolio.

Stakeholder Impact

• Shareholders will benefit from the strong financial results and increased outlook.
• Employees may see positive impacts from the company's growth and success.
• Patients will benefit from the development of new treatments and therapies.
• Customers will have access to a broader range of products and services.
• Suppliers and creditors will benefit from the company's financial stability.

Next Steps

• Merck will host an Oncology Investor Event on June 3, 2024.
• The company has three PDUFA target action dates set by the FDA in the second quarter of 2024.
• Merck will continue to advance its clinical development programs and expand its pipeline through business development.

Key Dates

Keywords

Merck, Oncology, Vaccines, KEYTRUDA, GARDASIL, WINREVAIR, Pharmaceuticals, Financial Results, Earnings, Sales, Acquisition, Pipeline, FDA Approval